Nancy Simonian, MD, discusses the results at ASH 2018.
Although PFS with ibrutinib-containing regimens was favorable compared with bendamustine rituximab, overall survival was not different across the study arms.
Charles G. Mullighan, MBBS (Hons), MSc, MD, discusses the latest research out of St Jude at ASH 2018.
Joshua Zeidner, MD, discusses stage 1 findings at the ASH 2018 meeting.
Although CAR-T alone has shown utility in CLL, evidence suggests the addition of ibrutinib could improve the durability of remission.
Favorable data on liso-cel bolsters its chances of moving into further stages of development, provided complete responses remain durable.
Although the study suggested the efficacy of the branded version was superior to its generic counterpart, more research may be necessary to tease out manufacturer differences.
Rod A. Humerickhouse, MD, PhD, discusses findings from AbbVie at the ASH 2018 meeting.
Rod A. Humerickhouse, MD, PhD, discusses updated findings at the ASH 2018 meeting.
In patients who have been newly diagnosed with AP-CML, the initiation of TKI2 therapies in the frontline setting provided excellent responses and survival rates.
No Survival Benefit Found With Allogeneic Hematopoietic Cell Transplantation in Older Patients With AMLDecember 01, 2018
At first glance, the data on 695 patients with advanced myeloid leukemia (AML) seem to support a survival advantage of allogeneic hematopoietic cell transplantation (HCT) compared with no transplantation.
Cell surface antigen Siglec-6 was broadly expressed in chronic lymphocytic leukemia after transplantation, suggesting a new potential drug target.
There are several novel agents, such as ibrutinib, idelalisib, and venetoclax, that could improve outcomes in CLL patients with 17p deletions and TP53 mutations.
AID is a mutator enzyme that plays an essential role for somatic hypermutation and class switch recombination during effective adaptive immune responses.
There were no previously unknown AML-specific mutations or structural variations in immune-related genes among patients with AML who had undergone transplant.
A prototype intervention increased adherence to tyrosine kinase inhibitor therapy in some patients with chronic myeloid leukemia.
The majority of patients studied who stopped TKI therapy remained treatment-free at 3 years.
In mice models, the systemic delivery of blood platelets that were coated with anti-PD-1 antibodies and conjugated to HSCs halted the recurrence of leukemia.
Cost-effectiveness of TKIs for CML treatment is a complex topic that requires consideration of multiple factors — not just apparent costs to payers.
A regimen showed favorable minimal residual disease negativity in patients with high-risk CLL, allowing many to pursue transplantation.
There were 11 genes identified in BeatAML — called in at least 1% of patients — that were not originally recognized in previous AML sequencing studies.
Immune changes in the tumor microenvironment were associated with clinical response to lenalidomide in patients with chronic lymphocytic leukemia.
High comorbidity burden was associated with worse survival outcomes in patients with chronic lymphocytic leukemia who were treated with ibrutinib.
A new method for rapid, ultrasensitive detection of BCR-ABL1 mRNA in chronic myeloid leukemia was described; the tool may have diagnostic utility.
The Leukemia & Lymphoma Society partnered with Sutro Biopharma to test the safety of the investigational CD74-targeting antibody-drug conjugate STRO-001 for 2 blood cancers.
The addition of AR-42 to imatinib yielded synergistic activity in chronic myeloid leukemia cells and also appeared to reverse therapeutic resistance.
A matching-adjusted indirect comparison concluded that ponatinib offers better disease control compared with bosutinib in certain patients.
Duvelisib improved PFS by more than 3 months compared with ofatumumab, the current standard of care, in relapsed or refractory CLL and SLL.
Increased costs were found to be a result of more infections.
In patients with chronic lymphocytic leukemia, a lower ibrutinib dose appears to confer sufficient biological activity, but further study is needed.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- CAR-T Trial for Triple-Negative Breast Cancer Under Way
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Phase 3 GEICAM/CIBOMA Results: Adjuvant Capecitabine in Triple-Negative Breast Cancer
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma
- Younger Breast Cancer Patients at Higher Risk for Osteoporosis
- Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified
- Gly101Val Mutation Directly Causes Resistance to Venetoclax
- Can Treatments for Childhood ALL Alter the Gut Microbiome?